Below are the most recently updated broker updates which include ratings and price targets for Aduro Biotech, Inc. (NASDAQ:ADRO).

03/31/2016 – Broker: FBR Capital Markets Rating: outperform New Target: 30 reiteration

03/24/2016 – Broker: Roth Capital Rating: buy New Target: 46 reiteration

03/15/2016 – Broker: Bank of America Merrill Lynch Rating: underperform New Target: 14 downgrade

12/16/2015 – Broker: Canaccord Genuity Rating: buy reiteration

12/01/2015 – Broker: Oppenheimer Rating: perform New Target: 30 downgrade

11/24/2015 – Broker: William Blair Rating: outperform reiteration

11/24/2015 – Broker: Leerink Swann Rating: outperform New Target: 48 reiteration

The average price target from the most recent broker reports is 33.60

The stock decreased -3.33% (-0.40) during the last days session, reaching 11.63 and roughly 255037 shares were bought or sold by traders.

View other investors thoughts on Aduro Biotech, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.